med chem II quizzes

Card Set Information

med chem II quizzes
2013-05-04 12:04:36
med chem II quizzes

med chem II quizzes
Show Answers:

  1. approved for prophylactic use to reduce infection rates by HIV
    emtricitabine and tenofovir - truvada
  2. chemokine receptor 5 co-receptor antagonist used only in a CCR5-tropic HIV-1 detectable resistant strain
    maraviroc - selzentry
  3. most poorly tolerated of HIV protease inhibitor - severe diarrhea, flu-lke symptooms, POTENT CYP 3A/2D6 inhibitor - capsules must be refrigerated
    ritonavir - norvir
  4. azapeptide inibitor of HIV protease that is a potent inhibitor of glucuronidation by UGT1A1
    atazanavir - reyataz
  5. NNRTI with a black box warning against liver failure and >40% develop Steven-Johnsons syndrome
    nevirapine - viramune
  6. weakest NRTI - not used much today
    zalcitabine - hivid
  7. HIV protease inhibitor-rapidly dissolving capsule that must be taken with a high fat food to ensure proper absorption - use 2 tsp. peanut butter
    nelfinavir - viracept
  8. NRTI for anemia,neutropenia & initial therapy flu-like symptoms for weeks
    zidovudine - retrovir
  9. prophylactic vaccinaton against HPV type 16 and 18 that cause cervical cancers
  10. HIV drug use induced lipdystrophy treatment
    tesamorelin - egrifta
  11. HAART treatment results ina severe inflammatory response to opportunistic, infective agents present which may need further treatemen (ie. TB,Herpes,CMV)
    immune reconstitiution syndrome
  12. NRTI with severe hypersensitivity that can be determined by pharmacogenomics testing for the HLA-B*5701 gene polymorphism
    abacavir - ziagen
  13. NRTI indicated for pediatric use in patients over 3 months of age- not a CYP substrate/no inhibition of glucoronidation
    emtricitabine - emtriva
  14. HIV protease inhibitor that must be co-administered with 100 mg of ritonavir in order to inhibit CYP3A/2D6 to ensure sdequate plasma levels
    darunavir - prezista
  15. integrase strand inhibitor used in combo with other agents in resistant HIV strains
    raltegravie - isentress
  16. NNRTI agent - DO NOT use in combo with any other NNRTI due to increase resistance potential
    rilpivirine - endurant
  17. phosphate nucleotide analogue reverse transcroptase inhibitor with reduced activity against the K65R reverse transcriptas mutation (3% in USA)
    tenofovir - viread
  18. HIV protease inhibitor that is formulate with Vitamin E-accordingly NO vitamin E supplementation
    amprenavir - agenerase
  19. HIV protease inhibitor with severe diet limitations: no food or low protein/fat food only - must remain hydrated to prevent kidney stones - dispense in manufacturer bottle only
    indinavir - crixivan
  20. BID subcutaneous injection that interfers with the binding of the GP41 subunit of the viral envelope with the host cell cellular membrane preventing fusion
    enfuvirtide - fuzeon
  21. inhalation treatment of severe lower respiratory tract infection in pediatric patients infected with respiratory syncytial virus
    ribavirin - virazole
  22. used in combination with COpegus and Pagasys - a hepatitis C NS3/4A serine protease inhibitor
    telaprevir - incivek
  23. the most successful approach to date for the prevention of influenza
  24. cleaves sialic acid-glycoproteins - facilitates the spread of newly replicated virus & greatly increases pathogenicity of an influenza strain
  25. topical for oral/facial Herpes simplex - prodrug that blocks fusion of the virus with the host cell by altering the host cell membrane fluidity
    docosanol - abreva
  26. IV delivery neuraminidase inhibitor for susceptible strains of influenza available for serious infections by H1N! vai the CDC
    • peramivir
    • only used in cytomegalovirus infections in immune-compromised or transplant patients
  27. only used in cytomegalovirus infections in immunecompromised or transplan patients
    ganciclovir - cytovene
  28. used in combo therapy with Pegasys - PEGylated alfa-2a interferon to treat Hepatitis C
    rivavirin - CoPegus
  29. treatmetn of chronic hepatitis B- unmodified beta-L-enantiomer of thymidine
    telbivudine - tyzeka
  30. formerly used for influenza A - useful in carbon monoxide induced parkinson's like symptoms
    amantadine - symmetrel
  31. oral use only prodrug of Penciclovir used in acute shingles and genital herpes
    famciclovir - famvir
  32. topical agent for herpes simplex keratitisi of the eye
    idoxuridine - herplex
  33. the adamantadine class of drugs are no longer recommended due to complete resistance to these agents
    influenza A
  34. renal toxic agent that selectively inhibits pyrophosphate bonding site of virus-specific DNA polymerase
    foscarnet - foscavir
  35. blocks the renal tubular excretion of neuraminidase inhibitors
  36. inhalation delivery neuraminidase inhibitor for susceptible strains of influenza
    zanamivir - relenza
  37. primary enzymatic target of phosphorylated nucleoside class anti-viral agents which prevents DNA replication & leads to chain termination
    DNA polymerase
  38. IM monoclonal antibody - prevents protein mediated cell-to-cell fusion of RSV-infected cells by binding to the epitope of the A antigenic site
    palivizumab - synagis
  39. prodrug of acyclovir for HSV-1 and 2, shingles, epstein-barr mononucleosis, varicella chicken pox
    valacyclovir - valtrex
  40. oral delivery neuraminidase inhibitor for susceptible strains of influenza
    oseltamivir - tamiflu
  41. coronary infarction
    aVR- & ST segment depression
  42. ADP receptor thienopyridine which does NOT require prodrug actiation by CYP2C19
    prasugrel - effient
  43. PPI drug of choice for a GERD patient that must also concurrently take ticlopidine or clopidogrel
    lansoprazole - prevacid
  44. reduces platelet numbers/aggregation in essential thrombocythermia
    anagrelide - agrylin
  45. cellular proliferation (mTOR) inhibitors that are a component of a drug eluting stent
    sirolimus, paclitaxel, eveolimu
  46. non-peptide-based competitive inhibitor of integrin receptor and prevents platelet aggregation
    tirofiban -aggrestat
  47. blockade of this receptor system on a platelet prevents the exposure/appearance of the integrin receptors so no fibrinogen corsslinking mediated platelet aggregation occurs
    ADP receptor blockade
  48. in-stent neointimal hyperplasia which can be inhibited by cellular proliferation inhibitors (rapaycin analogs)
  49. intervnentional device which is more prone to thrombus formation if anti-platelet therapy is idscontinued prematurally
    drug eluting CV stents
  50. phosphodiesterase II inhibitor used in intermittent claudicatoin
    cilostazol - pletal
  51. PPI drug in which one of the enantiomers of this racemic mixture is a potent CYP2C19 inhibitor leading to possible treatment failure with ticlopidine or clopidogrel
    omeprazole - prilosec
  52. irreversible inhibitor of ADP induced platelet aggregation for the entire lifetime of a platelet
    thienopyridine class anti-platelet drugs
  53. coronary ischemia
    ST-segment elevation
  54. second metabolic event that result in the opening of the thienopyridine thioester group and generaton of the sufenic acid electrophile that actually reacts with the platelet ADP binding site nucleophile that results in irreversible inihibition
    CyP450, oxygen, NADPH
  55. prevents the crosslinking of platelets mediated by fibrinogen binding
    integrin RGD receptor blockade
  56. peptide-based competitive inhibitor of integrin receptor and prevents platelet aggregation
    eptifibatide - integrillin
  57. interventional device which is more prone to develope overgrowth of epithelial cells leading to in-stent occlusion that is not thrombus based
    integrin RGD receptor blockade
  58. cyclooxygenase based inhibitor used prophylactically with many other anti-platelet drugs to prevent platelet aggregate induce thrombus formation in arteries
    eptifibatide - integrillin
  59. monoclonal antibody which blocks integrin receptor and prevents platelet aggregation
    abciximab - ReoPro
  60. mechanical issues involved with balloon angioplasty and stent deplyment that contribute to platelet activation
    collagen exposure, turbulent flow